| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
In the preceding three months, 6 analysts have released ratings for Harmony Biosciences (NASDAQ:HRMY), presenting a wide array of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 0 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 2 | 0 | 0 | 0 | 0 |
| 3M Ago | 3 | 0 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Harmony Biosciences, presenting an average target of $52.0, a high estimate of $56.00, and a low estimate of $48.00. This current average has not changed from the previous average price target.
In examining recent analyst actions, we gain insights into how financial experts perceive Harmony Biosciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Ashwani Verma | UBS | Announces | Buy | $56.00 | - |
| Ami Fadia | Needham | Maintains | Buy | $52.00 | $52.00 |
| Ami Fadia | Needham | Maintains | Buy | $52.00 | $52.00 |
| Ami Fadia | Needham | Maintains | Buy | $52.00 | $52.00 |
| Ami Fadia | Needham | Maintains | Buy | $52.00 | $52.00 |
| David Hoang | Citigroup | Announces | Buy | $48.00 | - |
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Harmony Biosciences's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Harmony Biosciences analyst ratings.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Harmony Biosciences's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 28.76% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Harmony Biosciences's net margin excels beyond industry benchmarks, reaching 6.71%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Harmony Biosciences's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.2%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Harmony Biosciences's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.36%, the company showcases efficient use of assets and strong financial health.
Debt Management: Harmony Biosciences's debt-to-equity ratio is below the industry average at 0.35, reflecting a lower dependency on debt financing and a more conservative financial approach.
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: HRMY
